熱門資訊> 正文

Intelligence Therapeutics以折扣价定价1.8亿美元股票发行

2026-04-29 20:50

Intellia Therapeutics (NTLA) on Wednesday said it priced an underwritten public offering of 16.74M shares at $10.75 each, for expected gross proceeds of about $180M.
Shares down -11% in premarket. The stock closed at $13.2 on Tuesday.
The company is selling all shares in the offering. It also granted underwriters a 30-day option to purchase up to an additional 2.51M shares at the same price, less discounts and commissions.
Jefferies, Goldman Sachs, and Citigroup are acting as joint book-running managers.

More on Intellia Therapeutics

Intellia Therapeutics And Wall Street Continue To Play Their D&D Game - Data And Doubt
Intellia Therapeutics, Inc. (NTLA) Discusses Topline Phase 3 HAELO Trial Results for Lonvoguran Ziclumeran in Hereditary Angioedema - Slideshow
Intellia Therapeutics, Inc. (NTLA) Discusses Topline Phase 3 HAELO Trial Results for Lonvoguran Ziclumeran in Hereditary Angioedema Transcript
Intellia Therapeutics launches $150M public stock offering
Intellia jumps as FDA lifts clinical hold on nex-z for ATTR-CM

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。